From: 24/03/2017 to: 24/03/2017 4th ESO Prostate Cancer Observatory: innovation and care in the next 12 months, London, United Kingdom                                        From: 25/03/2017 to: 30/03/2017 16th ESO-ESMO Masterclass in Clinical Oncology, Nauen OT Groß Behnitz (Berlin area), Germany                                        From: 25/03/2017 to: 30/03/2017 10th ESO-EONS Masterclass in Oncology Nursing, Nauen OT Groß Behnitz (Berlin area), Germany                                        From: 12/04/2017 to: 13/04/2017 9th Clinical Oncology Update - Onkologia 2017, Krakow, Poland                                        From: 26/04/2017 to: 30/04/2017 3rd ESO-ESMO Latin-American Masterclass in Clinical Oncology, San Jose, Costa Rica                                        From: 7/05/2017 to: 7/05/2017 4th ESO Lung Cancer Observatory, Geneva, Switzerland                                        From: 18/05/2017 to: 19/05/2017 Eurasia Course on Gastrointestinal Malignancies, Moscow, Russian Federation                                        From: 22/05/2017 to: 26/05/2017 3rd ESOP-ESO Advanced Masterclass in Oncology Pharmacy, Lisbon, Portugal                                        From: 26/05/2017 to: 27/05/2017 ESMO Preceptorship on Immuno-Oncology 2017, Amsterdam, The Netherlands                                        From: 10/06/2017 to: 13/06/2017 Leukaemia and Lymphoma, Ascona, Switzerland                                        From: 21/06/2017 to: 23/06/2017 Masterclass in Oncology Basics for Beginners, Cambridge, United Kingdom                                        From: 30/06/2017 to: 05/07/2017 4th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology, Belgrade, Serbia                                        From: 13/07/2017 to: 18/07/2017 ESMO-ESO Course on Medical Oncology for Medical Students, Valencia, Spain                                        From: 28/08/2017 to: 08/09/2017 ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students, Antwerp, Belgium                                        From: 06/10/2017 to: 07/10/2017 Eastern Europe and Balkan Region Refresher Course on Breast Cancer, Krakow, Poland                                        From: 18/10/2017 to: 20/10/2017 4th Masterclass in Clinical Oncology, Tbilisi, Georgia                                        From: 18/10/2017 to: 18/10/2017 ESO Breast Cancer Observatory, Tehran, Iran                                        From: 02/11/2017 to: 04/11/2017 ESO-ESMO Advanced Breast Cancer Fourth International Consensus Conference (ABC4), Lisbon, Portugal                                        From: 02/12/2017 to: 04/12/2017 ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, Milan, Italy                                        From: 15/12/2017 to: 18/12/2017 1st Mediterranean Masterclass in Clinical Oncology, Limassol, Cyprus

Curriculum

 

 

Attendance 1 

Module 1 

Module 2 

Attendance 2 

Module 3 

Module 4 

Attendance 3 

Total 

 Timetable 

 2017
2 Feb - 5 Feb

2017
Feb/Mar 

2017
April/mid Jun 

2017
10-14 June 

2017
Mid Jun-Nov

2017-2018
Dec-Apr

2018
25-28 April 

14 months 

 Content

 CCL course + 
IOSI course

Topic 1
Basic research,
epidemiology
and
pathology

Campo
Gaidano

 Topic 2
Principles of
diagnostics,
management
and
clinical trials

Lister
Hagenbeek
Gospodarowicz
 

ESO course
and
ICML Conf.

 Topic 3
Lymphoma
subtypes I

Zucca
Vose
Coiffer

Topic 4
Lymphoma
subtypes II

Engert
Federico 

CCL course
Ulm
 

 

 Workload

 25 hrs
In-person

20 units
60 hrs
Distance
learning
+ test

 30 units
90 hrs
Distance
learning
+ test

25 hrs
In-person

30 units
90 hrs
Distance learning
+ test 

30 units
90 hrs
Distance
learning
+ test 

25 hrs
In-person
+
Certificate
exam

75 hrs
In-person
+
330 hrs
Distance
learning
405 hrs

 Credits

1 ECTS 

2 ECTS 

3 ECTS 

1 ECTS 

3 ECTS 

3 ECTS 

1 ECTS 

14 ECTS 

         
CCL:separate and specific seminar for Certificate of Competence in Lymphoma participants
  
IOSI course: join the course held by the Oncology Institute of Southern Switzerland (IOSI - Bellinzona, Switzerland) 
  
ESO course: join sessions of the ESO Advanced Course on Leukaemia and Lymphoma (Ascona, Switzerland)
  
ICML:join the Closed Workshop of the International Conference on Malignant Lymphoma (Lugano, Switzerland)
 

 

The extensiveness of the Module’s programme is expressed in Units.
1 Unit equals to 3 hours of workload, consisting of a 30-minute lecture and 2,5 hours of additional reading.
For instance:
2 Units = 6 hours of workload = 60-minute lecture + 5 hours of additional reading.
  
 Seminar/Module  Topics 

Units 

Workload
hours 

ECTS 

Comment 

 Seminar 1:

 CCL 

 IOSI
 
 Course:
 2-5 Feb 2017  
 Bellinzona,
 Switzerland


 

 25

 1

No exam
 Programme will follow






































 Module 1:

 Basic research,
 epidemiology
 and pathology
 of lymphoma
 Giancarlo Gaidano, Randy Gascoyne

20

60 

Test (40q) 

 Gene structure, gene expression and mutations in
 lymphoma
 [Ryan Morin]

 2

   
 Micro RNAs and Lymphoma
 [George Calin]

 2

   
 Signalling pathways
 [Ralph Küppers]

 2

   
 Apoptotic pathways
 [Francesco Bertoni]

 2

   
 Tumor suppressor genes and oncogenes
 [Laura Pasqualucci]

 2

   
 Microenvironment
 [Pedro Farinha]

 2

   
 Epigenetics
 [Daniel Mertens]

 2

   
 Immune system and lymphoma
 [Mariagrazia Uguccioni]

 2

   
 Epidemiology
 [Diego Serraino]

 2

   
 Pathology (principles of the current classification)
 [Stefano Pileri]

 2

   

 Learning
 objectives

 Participants will:
• Update their knowledge in basic research, epidemiology and pathology of lymphoma.
• Update their knowledge concerning the biology of lymphoma, learn about genetic features of lymphoma, molecular targets in lymphoma and the role of the immune system on lymphoma development.
• Update their knowledge in the epidemiology of different lymphoid malignancies.
• Update their knowledge concerning distinct pathological measurements to diagnose lymphoma accurately and learn about different techniques and their diagnostic application.

 Module 2:

 Principles of
 diagnostic,
 management
 and clinical
 trials
 Andrew Lister, Anton Hagenbeek, Mary Gospodarowicz

 30

90 

test (60q) 

 Diagnostic procedures:    
 - Diagnosis on lymph node biopsy, including
   knowledge on immunophenotyping, specific
   cytogenetics, molecular diagnostics, gene
   profiling etc.
   [Daphne de Jong]

 1

   
 - Initial work-up
   (physical examination, bone-marrow biopsy,
   laboratory and imaging). Establishing the stage
   of disease, A or B
   [Silvia Montoto]

 1

   
 Principles of treatment:

 

   
 - Chemo- and immune-chemotherapy, including
   autologous stem cell transplant
   [Jonathan W. Friedberg]

 2

   
- Antibodies,vaccines, PD1 / PDL1
  [Emanuele Zucca] 
 2   
- Allogeneic stem cell transplant
  [Jakob Passweg]

 2   
 - Radiotherapy [Berthe Aleman]

 1

   
 - Targeted treatment with e.g. antibody
   drug-conjugates, radio-immunotherapy
   , etc.
   [Julie M. Vose]

 1

   
 - T-cell lymphomas [Julie M. Vose]

 1

   
 Prognostic and predictive factors:

 

   
 - FLIPI/IPI [Laurie Sehn]

 1

   
 - Molecular prognostic factors [Georg Lenz]

 1

   
 - Imaging [Sally Barrington]

 2

   
 Management of clinical trials:

 

   
 - Design and interpretation of clinical trials
   [Richard Schlenk]

 1

   
 - Meta-analysis and systematic review
   [Dietrich Rothenbacher]

 1

   
 - Planning and performance of clinical trials 
   (introduction to good clinical practice)
   [Anastasios Stathis]

 1

   
 - Development of a protocol: from the
   idea to the protocol writing
   [Anastasios Stathis]

 1

   
 - Evaluation and publication of clinical trials
   [Bruce Cheson]

 1

   
 - Sponsor responsibility
   [Nikolai Brun]

 1

   
 - Management of a clinical trial database
  
[Richard Schlenk]

 1

   
 - Cost evaluation and control, including funding
   [Gerhard Held]

 1

   
 - Transfer of study results into clinical practice
   [James O. Armitage]                     

 1

   
 Evaluation of treatment results:

 

   
 - Response criteria and follow-up schedule
  
[Bruce Cheson]

 1

   
 - Minimal residual disease
   [Alessandro Rambaldi]

 1

   
 The challenge of translational research:    
 - Integrating molecular biology with clinical trials
   [Kieron Dunleavy]

 1

   
 - Management of biobanks
   [Peter Moeller]

 2

   
 Learning
 objectives
 Participants will:
• Acquire and develop effective skills to advance the practice of clinical research in lymphoma.
• Acquire the capability of analysing and evaluating contemporary issues in clinical research and in good-clinical practice.
• Update their knowledge concerning design and interpretation of clinical trials, systemic reviews and meta-analyses.
• Acquire skills on how to manage a clinical trial.
• Update their knowledge on how to manage lymphoma patients on an evidence-based approach and will be able to transfer the current evidence-based guidelines into daily clinical practice.
• Acquire state-of-the-art knowledge as recommended by international experts and guidelines and treatment protocols developed nationally and internationally.
• Learn about haematological diagnostic procedures (immunophenotyping).
• Learn about imaging techniques and their indications in lymphoma.
• Learn about distinct principles of therapy of lymphoid malignancies.
• Update their knowledge concerning response evaluation, response criteria and follow-up schedules.

 Seminar 2:
 
 ESO / ICML
 
 Course:
 10-14 Jun 2017
 Leukaemia and
 Lymphoma,
 Ascona,
 Switzerland

 ICML Closed
 Workshop,
 Lugano,
 Switzerland


 

 25

 1

 No exam
 Programme will follow    

    

    

    

    



































 Module 3:

 Lymphoma
 subtypes
 Part I:

 Mature B-cell
 neoplasms
 Emanuele Zucca, Julie M. Vose, Bertrand Coiffer

 30

 90

 3

Test (60q)

 CLL/SLL/B-PLL (indolent):

 

   
 - Pathogenesis and B-cell signalling
   [Ralph Küppers]

 1

   
 - First line treatment of CLL
   [Stephan Stilgenbauer]

 1

   
 - Treatment of relapsed / refractory CLL
   [Manuela Bergmann]

 1

   

 - Chronic lymphocytic leukemia:
   Diagnostic criteria and initial workup
   [Emili Montserrat]

 1

   
 Lymphoplasmacytic lymphoma / Waldenström´s
 Macroglobulinemia
 [Eva Kimby]

 1

   
 - Primary amyloidosis
   [Angela Dispenzieri]

 1

   
 - Hairy cell leukaemia
   [Francesco Forconi]

 1

   
 Follicular lymphoma:

 

   
 - Natural history of follicular lymphoma and
   unmet clinical needs
   [T. Andrew Lister]

 1

   
 - Front-line treatment at relapse
   [Gilles Salles]

 1

   

 - Is there room for a non-chemotherapy based
   approach?
   [Michele Ghielmini]

 1

   
 Marginal zone lymphoma (nodal and extranodal)
 (gastric and non-gastric MALT lymphoma, nodal
 marginal zone lymphoma, splenic marginal zone
 lymphoma):

 

   
 - MALT
   [Franco Cavalli]

 1

   
 - Non-MALT
   [Chaterine Thieblemont]

 1

   
 Mantle cell lymphoma
 [Martin Dreyling]

 2

   
 Diffuse large B-cell lymphoma (agressive):

 

   
 - Treatment of localised DLBCL
   [Joseph M. Connors]

 1

   

 - Treatment of advanced-stage DLBCL
   [James O. Armitage]

 2

   
 - Relapsed and refractory DLBCL
   [Christian Gisselbrecht]

 1

   
 - Primary mediastinal large B-cell lymphoma
   [Andrew Davies]

 1

   
 - Burkitt lymphoma
   [Ian Magrath]

 1

   
 Richter syndrome
 [Davide Rossi]

 1

   
 Immunodeficiency associated lymphoma 
 (EBV, HHV-8, HTLV-I, HIV, HCV) and post transplant
 [Kieron Dunleavy]

 2

   
 Extranodal lymphoma (CNS, testes)
 [Andrès Ferreri]

 2

   
 Primary cutaneous B-cell lymphoma
 [Werner Kempf]

 1

   
 Clonal lymphoid populations of uncertain malignant
 potential 

 1

   
 Plasma cell disorders
 [Antonio Palumbo]

 2

   
 Management of lymphoma in the elderly patient
 [Joseph M. Connors]

 1

   
 Learning
 objectives
 (Mod 3 and 4)
  Participants will:
• Acquire problem-solving-strategies through case discussions with respect to the individual and critical dimensions of treatment.
• Broaden the clinical skills in diagnosing mature B-cell neoplasms, PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma.
• Be able to design and customise treatment plans for mature B-cell neoplasms PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma.
• Understand clinical differences in the pathological processes and treatment.
• Be able to design and customise treatment plans for special subgroups of lymphoma patients.
 Module 4:


 Lymphoma
 subtypes
 Part II:

 PTLD,
 T-cell and
 NK-cell
 neoplasms
 and Hodgkin
 lymphoma
 Andreas Engert, Massimo Federico

 30

90 

Test (60q) 

 PTLD
 [Andrew Evens]

 2

   
 T-PLL and T-LGL
 [Claire Dearden]

 1

   
 Adult T-cell leukaemia/lymphoma
 [Ruth Pettengell]

 1

   
 Mycosis Fungoides, Sezary syndrome, cutaneous T-cell
 lymphoma
 [Emilio Berti]

 1

   
 Peripheral T-cell lymphoma, non-cutaneous
 
[Andrea Gallamini]

 2

   
 Extranodal NK/T-cell lymphoma, nasal type
 [Won Seong Kim]

 1

   
 Anaplastic large cell lymphoma, ALK positive and
 negative 
 [Kerry Savage]

 1

   
 Hodgkin lymphoma (HL):

 

   
 - Classical HL and nodular lymphocyte-predominant HL
   [Dennis Eichenauer]

 2

   
 - Treatment of early-stage HL
   [Bastian von Tresckow]

 1

   
 - Treatment of advanced-stage HL
   [Massimo Federico]

 1

   

 - Treatment of relapsed/refractory HL
   [Massimo Federico]

 1

   
 - Long-term complications of HL therapy
   [Stefano Luminari]

 1

   
 Histiocytic and dendritic cell neoplasms
 [Stefano Pileri]

 2

   
 Mastocytosis
 [Zbigniew Rudzki]

 1

   
 Gray zone lymphoma
 [Stefano Pileri]

 1

   
 Paediatric Hodgkin lymphoma
 [Monika Metzger]

 1

   
 Paediatric non-Hodgkin lymphoma
 [John T. Sandlund]
 1   
 Tumour Lysis syndrome and renal problems
 [Bertrand Coiffier]

 2

   
 Lymphoma and rheumatologic disorders
 [Stefano Sacchi]

 2

   
 Lymphoma and neurological disorders
 [Andrès Ferreri]

 2

   
 Lymphoma in pregnancy
 [Fedro A. Peccatori]

 1

   
 Lymphoma and fertility
 [Dror Meirow]

 1

   
 Familiar lymphoma
 [Stefano Luminari]

 1

   
 Learning
 objectives
 (Mod. 3 and 4)
 Participants will:
• Acquire problem-solving-strategies through case discussions with respect to the individual and critical dimensions of treatment.
• Broaden the clinical skills in diagnosing mature B-cell neoplasms, PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma.
• Be able to design and customise treatment plans for mature B-cell neoplasms PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma.
• Understand clinical differences in the pathological processes and treatment.
• Be able to design and customise treatment plans for special subgroups of lymphoma patients.
 Seminar 3:

 Ulm, Germany
 April 2018

 

25 

Certificate
Exam
(110q)* 

 Programme will follow     
 

Examination regulations (Module Tests and Certificate Examination)

At the end of each module participants have to pass a mandatory online test that has to be submitted to Ulm University. Only participants who passed the four tests will have access to the Certificate Exam at the end of the Programme.

Module Tests:

The written multiple-choice Module Test is deemed to have been passed if a minimum of 60% of the questions were answered correctly.

Module Tests are not graded and can be re-taken as often as necessary until the Test is passed.

Certificate Examination:

The Certificate Exam will be held using prepared Ulm University computers (not participants’ personal laptops) and it can only be taken at Seminar 3 of the Programme.

The written multiple-choice Certificate Examination is deemed to have been passed if a minimum of 60% of
the questions were answered correctly. The grades are as follows:

1 = very good, 90% or more;
2 = good, 80% or more but less than 90%;
3 = satisfactory, 70% or more but less than 80%;
4 = sufficient, 60% or more but less than 70%;
5 = insufficient, less than 60%.

The Examination is also deemed to have been passed if the number of questions answered correctly by the participant falls short of the average examination result for all first-time examinees for this examination by no more than 10% provided that the examinee answered a minimum of 50% of the questions correctly.

Failed Examination may be re-taken twice but only within the time of attendance of Seminar 3, or during the next Programme Seminar of the following cohort.